Contrast, motion, perceptual integration, and neurocognition in schizophrenia: The role of fragile-X related mechanisms

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 46, Issue , 2013, Pages 92-97

  Kelemen, Oguz ^a   Kovács, Tamás ^b   Kéri, Szabolcs ^b,c,d  

^a BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

^b NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

Author keywords

Fragile X Syndrome; Neurocognition; Schizophrenia; Visual perception

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; FRAGILE X MENTAL RETARDATION PROTEIN; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; ATTENTION; CELL LEVEL; CLINICAL ARTICLE; COGNITION; CONTRAST SENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; MOVEMENT PERCEPTION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROCOGNITION; PATHOGENESIS; PATTERN RECOGNITION; PERCEPTION; PERCEPTUAL INTEGRATION; PERIPHERAL LYMPHOCYTE; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; VISION;

ANALYSIS OF VARIANCE; ANOVA; FMRP; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; FXS; GABA; GAMMA-AMINOBUTYRIC ACID; HONESTLY SIGNIFICANT DIFFERENCE; HSD; M; MAGNOCELLULAR; NEUROCOGNITION; P; PANSS; PARVOCELLULAR; POSITIVE AND NEGATIVE SYNDROME SCALE; RBANS; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SF; SPATIAL FREQUENCY; TEMPORAL FREQUENCY; TF; VISUAL PERCEPTION;

ADULT; BIOLOGICAL MARKERS; COGNITION DISORDERS; CONTRAST SENSITIVITY; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MOTION PERCEPTION; PHOTIC STIMULATION; SCHIZOPHRENIA;

EID: 84880938430     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.06.017     Document Type: Article

References (59)

1. Bear M.F., Dölen G., Osterweil E., Nagaraja N. Fragile X: translation in action. Neuropsychopharmacology 2008, 33:84-87.
2. Bourgeois J.A., Coffey S.M., Rivera S.M., Hessl D., Gane L.W., Tassone F., et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry 2009, 70:852-862.
3. Butler P.D., Martinez A., Foxe J.J., Kim D., Zemon V., Silipo G., et al. Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain 2007, 130:417-430.
4. Butler P.D., Silverstein S.M., Dakin S.C. Visual perception and its impairment in schizophrenia. Biol Psychiatry 2008, 64:40-47.
5. Butler P.D., Chen Y., Ford J.M., Geyer M.A., Silverstein S.M., Green M.F. Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS. Schizophr Bull 2012, 38:81-91.
6. Calderone D.J., Martinez A., Zemon V., Hoptman M.J., Hu G., Watkins J.E., et al. Comparison of psychophysical, electrophysiological, and fMRI assessment of visual contrast responses in patients with schizophrenia. Neuroimage 2013, 67:153-162.
7. Chen Y. Abnormal visual motion processing in schizophrenia: a review of research progress. Schizophr Bull 2011, 37:709-715.
8. Dakin S., Frith U. Vagaries of visual perception in autism. Neuron 2005, 48:497-507.
9. de Haan E.H., Cowey A. On the usefulness of 'what' and 'where' pathways in vision. Trends Cogn Sci 2011, 15:460-466.
10. Devys D., Lutz Y., Rouyer N., Bellocq J.P., Mandel J.L. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet 1993, 4:335-340.
11. Fatemi S.H., Folsom T.D. The role of fragile X mental retardation protein in major mental disorders. Neuropharmacology 2011, 60:1221-1226.
12. Fatemi S.H., Kneeland R.E., Liesch S.B., Folsom T.D. Fragile X mental retardation protein levels are decreased in major psychiatric disorders. Schizophr Res 2010, 124:246-247.
13. Fatemi S.H., Folsom T.D., Kneeland R.E., Liesch S.B. Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anat Rec (Hoboken) 2011, 294:1635-1645.
14. Fatemi S.H., Folsom T.D., Rooney R.J., Thuras P.D. mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry 2013, 3:e271.
15. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1996, American Psychiatric Press, Washington, DC.
16. Gilbert C.D. The constructive nature of visual perception. Principles of neural sciences 2013, 556-576. McGraw Hill, New York. E.R. Kandel, J.H. Schwartz, T.M. Jessel, S.A. Siegelbaum, A.J. Hudspeth (Eds.).
17. Glass L. The Moire effect from random dots. Nature 1969, 223:578-580.
18. Gold J.M., Queern C., Iannone V.N., Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry 1999, 156:1944-1950.
19. Goodbourn P.T., Bosten J.M., Hogg R.E., Bargary G., Lawrance-Owen A.J., Mollon J.D. Do different 'magnocellular tasks' probe the same neural substrate?. Proc Biol Sci 2012, 279:4263-4271.
20. Graham D., Meng M. Altered spatial frequency content in paintings by artists with schizophrenia. i-Perception 2011, 2:1-9.
21. Hagerman R., Hoem G., Hagerman P. Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Mol Autism 2010, 1:12.
22. Halász I., Levy-Gigi E., Kelemen O., Benedek G., Kéri S. Neuropsychological functions and visual contrast sensitivity in schizophrenia: the potential impact of comorbid posttraumatic stress disorder (PTSD). Front Psychol 2013, 4:136.
23. Heulens I., Kooy F. Fragile X syndrome: from gene discovery to therapy. Front Biosci 2011, 16:1211-1232.
24. Iwahashi C., Tassone F., Hagerman R.J., Yasui D., Parrott G., Nguyen D., et al. A quantitative ELISA assay for the fragile x mental retardation 1 protein. J Mol Diagn 2009, 11:281-289.
25. Juhász L.Z., Kemény K., Linka E., Sántha J., Bartkó G. The use of RBANS test (Repeatable Battery for the Assessment of Neuropsychological Status) in neurocognitive testing of patients suffering from schizophrenia and dementia. Ideggyogy Sz 2003, 56:303-308.
26. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
27. Kéri S., Benedek G. Visual pathway deficit in female fragile X premutation carriers: a potential endophenotype. Brain Cogn 2009, 69:291-295.
28. Kéri S., Benedek G. Fragile X protein expression is linked to visual functions in healthy male volunteers. Neuroscience 2011, 192:345-350.
29. Kéri S., Benedek G. Why is vision impaired in fragile X premutation carriers? The role of fragile X mental retardation protein and potential FMR1 mRNA toxicity. Neuroscience 2012, 206:183-189.
30. Kéri S., Kelemen O., Benedek G., Janka Z. Vernier threshold in patients with schizophrenia and in their unaffected siblings. Neuropsychology 2004, 18:537-542.
31. Kéri S., Kiss I., Kelemen O., Benedek G., Janka Z. Anomalous visual experiences, negative symptoms, perceptual organization and the magnocellular pathway in schizophrenia: a shared construct?. Psychol Med 2005, 35:1445-1455.
32. Kéri S., Kelemen O., Benedek G., Janka Z. Lateral interactions in the visual cortex of patients with schizophrenia and bipolar disorder. Psychol Med 2005, 35:1043-1051.
33. Kéri S., Benedek G., Janka Z. Vernier threshold and the parallel visual pathways in bipolar disorder: a follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:86-91.
34. Kéri S., Szamosi A., Benedek G., Kelemen O. How does the hippocampal formation mediate memory for stimuli processed by the magnocellular and parvocellular visual pathways? Evidence from the comparison of schizophrenia and amnestic mild cognitive impairment (aMCI). Neuropsychologia 2012, 50:3193-3199.
35. Kogan C.S., Boutet I., Cornish K., Zangenehpour S., Mullen K.T., Holden J.J., et al. Differential impact of the FMR1 gene on visual processing in fragile X syndrome. Brain 2004, 127:591-601.
36. Kovács I. Gestalten of today: early processing of visual contours and surfaces. Behav Brain Res 1996, 82:1-11.
37. Kovács T., Kelemen O., Kéri S. Decreased fragile X mental retardation protein (FMRP) is associated with lower IQ and earlier illness onset in patients with schizophrenia. Psychiatry Res 2013, [2013 Jan 17. doi:pii: S0165-1781(12)00845-1]. 10.1016/j.psychres.2012.12.022.
38. Laycock R., Crewther S.G., Crewther D.P. A role for the 'magnocellular advantage' in visual impairments in neurodevelopmental and psychiatric disorders. Neurosci Biobehav Rev 2007, 31:363-376.
39. Martínez A., Hillyard S.A., Dias E.C., Hagler D.J., Butler P.D., Guilfoyle D.N., et al. Magnocellular pathway impairment in schizophrenia: evidence from functional magnetic resonance imaging. J Neurosci 2008, 28:7492-7500.
40. McBain R., Norton D., Chen Y. Differential roles of low and high spatial frequency content in abnormal facial emotion perception in schizophrenia. Schizophr Res 2010, 122:151-155.
41. McKendrick A.M., Badcock D.R., Gurgone M. Vernier acuity is normal in migraine, whereas global form and global motion perception are not. Invest Ophthalmol Vis Sci 2006, 47:3213-3219.
42. Must A., Janka Z., Benedek G., Kéri S. Reduced facilitation effect of collinear flankers on contrast detection reveals impaired lateral connectivity in the visual cortex of schizophrenia patients. Neurosci Lett 2004, 357:131-134.
43. Nassi J.J., Callaway E.M. Parallel processing strategies of the primate visual system. Nat Rev Neurosci 2009, 10:360-372.
44. O'Donnell W.T., Warren S.T. A decade of molecular studies of fragile X syndrome. Ann Rev Neurosci 2002, 25:315-338.
45. O'Donnell B.F., Swearer J.M., Smith L.T., Nestor P.G., Shenton M.E., McCarley R.W. Selective deficits in visual perception and recognition in schizophrenia. Am J Psychiatry 1996, 153:687-692.
46. O'Donnell B.F., Potts G.F., Nestor P.G., Stylianopoulos K.C., Shenton M.E., McCarley R.W. Spatial frequency discrimination in schizophrenia. J Abnorm Psychol 2002, 111:620-625.
47. Pieretti M., Zhang F.P., Fu Y.H., Warren S.T., Oostra B.A., Caskey C.T., et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991, 66:817-822.
48. Polat U., Sagi D. Lateral interactions between spatial channels: suppression and facilitation revealed by lateral masking experiments. Vision Res 1993, 33:993-999.
49. Randolph C., Tierney M.C., Mohr E., Chase T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998, 20:310-319.
50. Roder V., Medalia A. Neurocognition and social cognition in schizophrenia patients: basic concepts and treatment 2010, Karger, Basel.
51. Rousseau F., Labelle Y., Bussières J., Lindsay C. The fragile X mental retardation syndrome 20years after the FMR1 gene discovery: an expanding universe of knowledge. Clin Biochem Rev 2011, 32:135-162.
52. Sawatari A., Callaway E.M. Convergence of magno- and parvocellular pathways in layer 4B of macaque primary visual cortex. Nature 1996, 380:442-446.
53. Schechter I., Butler P.D., Zemon V.M., Revheim N., Saperstein A.M., Jalbrzikowski M., et al. Impairments in generation of early-stage transient visual evoked potentials to magno- and parvocellular-selective stimuli in schizophrenia. Clin Neurophysiol 2005, 116:2204-2215.
54. Sharma T., Harvey P. Cognition in schizophrenia. Impairments, importance, and treatment strategies 2000, Oxford University Press, Oxford.
55. Silverstein S.M., Keane B.P. Perceptual organization impairment in schizophrenia and associated brain mechanisms: review of research from 2005 to 2010. Schizophr Bull 2011, 37:690-699.
56. Skottun B.C., Skoyles J.R. Contrast sensitivity and magnocellular functioning in schizophrenia. Vision Res 2007, 47:2923-2933.
57. Willemsen R., Smits A., Mohkamsing S., van Beerendonk H., de Haan A., de Vries B., et al. Rapid antibody test for diagnosing fragile X syndrome: a validation of the technique. Hum Genet 1997, 99:308-311.
58. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64:663-667.
59. Zangenehpour S., Cornish K.M., Chaudhuri A. Whole-brain expression analysis of FMRP in adult monkey and its relationship to cognitive deficits in fragile X syndrome. Brain Res 2009, 1264:76-84.